- Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment - Sarepta sells at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results